Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Current Investments (2016 - 2024)

KalVista Pharmaceuticals' Cash & Current Investments history spans 10 years, with the latest figure at $268.3 million for Q4 2024.

  • For Q4 2024, Cash & Current Investments changed N/A year-over-year to $268.3 million; the TTM value through Dec 2024 reached $268.3 million, changed N/A, while the annual FY2024 figure was $210.4 million, N/A changed from the prior year.
  • Cash & Current Investments for Q4 2024 was $268.3 million at KalVista Pharmaceuticals, up from $135.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $268.3 million in Q4 2024 and bottomed at $50.3 million in Q1 2021.
  • The 4-year median for Cash & Current Investments is $91.9 million (2020), against an average of $117.5 million.
  • The largest annual shift saw Cash & Current Investments crashed 40.22% in 2020 before it skyrocketed 41.39% in 2024.
  • A 4-year view of Cash & Current Investments shows it stood at $55.9 million in 2020, then decreased by 9.96% to $50.3 million in 2021, then surged by 105.07% to $103.2 million in 2023, then soared by 160.09% to $268.3 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Cash & Current Investments are $268.3 million (Q4 2024), $135.8 million (Q4 2024), and $174.3 million (Q3 2024).